AVI BioPharma Initiates Clinical Development of a New Class of Antibiotics.
Business Wire › February 17, 2000
Linked as:
Extract
AVI BioPharma Initiates Clinical Development of a New Class of Antibiotics.
Business Editors, Health/Medical Writers
PORTLAND, Ore.--(BW HealthWire)--Feb. 17, 2000 New therapeutic class demonstrates additional applications of AVI's proprietary NEUGENE(R) antisense technology AVI BioPharma, Inc. (Nasdaq...See the full content of this document
Sponsored links
